Aurobindo Pharma: Clarification On Media Report 'Aurobindo Pharma Slips 5% After Detailed USFDA Observations To Unit 3'.
Ref : Email Dated June 4 2019 From BSE Ltd.

This has reference to your above cited email seeking clarification on the subject matter.

With reference to the above we inform you that the United States Food and Drug Administration (US FDA / Regulator) had conducted an inspection at our Companys Unit III a formulation manufacturing facility located at Bachupally Hyderabad from 13th May 2019 to 24th May 2019. In this regard the Company has received a Form 483 with ten observations. None of the observations are repetitive and are more procedural in nature. The Company will be responding to the US FDA within the stipulated time. The Form 483 will not have an impact on existing business of this facility.